Bibliography
- DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manage Dec Econ 2007;28:469-79
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Briefing: Cost of developing a new drug. Tufts University, Tufts Center for the Study of Drug Development, Boston, MA; 2014. Available from: http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014.pdf [Last accessed 15 December 2014]
- DiMasi JA, Feldman L, Seckler A, et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharm Therap 2010;87(3):272-7
- Grabowski H, Vernon J, DiMasi J. Returns on Research and Development for 1990s New Drug Introductions. PharmacoEcon 2002;20(Suppl 3):11-29
- Grabowski H, Long G, Mortimer R. Recent trends in brand name and generic drug competition. J Med Econ 2014;17(3):207-14
- Aitken M, Kleinrock M. IMS Institute for Healthcare Informatics. Medicine use and shifting costs of healthcare: a review of the use of medicines in the United States in 2013. Parsippany, NJ; 2014. Available from: http://www.imshealth.com/cds/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Secure/IIHI_US_Use_of_Meds_for_2013.pdf [Last accessed 12 January 2015]
- US Patent and Trademark Office Performance and Accountability Report Fiscal Year 2013. US Patent and Trademark Office. Washington, DC; 2013. Available from: http://www.uspto.gov/about/stratplan/ar/USPTOFY2013PAR.pdf [Last accessed 3 November 2014]
- Conti A, Thursby J, Thursby M. Patents as signals for startup financing. J Industrial Econ 2013;22:592-622
- Cockburn I. The changing structure of the pharmaceutical industry. Health Aff 2004;23(1):10-22
- Patient Capital 3.0. Confronting the Crisis and Achieving the Promise of Venture-Backed Medical Innovation. National Venture Capital Association, Washington, DC; 2013. Available from: http://www.nvca.org/PC3 [Last Accessed 3 November 2014]
- Mansfield E. Patents and Innovation: An Empirical Study. Management Sci 1986;32:2
- Levin R, Klevorick AK, Nelson RR, et al. Appropriating the returns from industrial research and development. Brook Papers Econ Activity 1987;3:783-832
- Cohen W, Nelson RR, Walsh JP, et al. Protecting their intellectual assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not). NBER Working Paper 2000;7552
- Arora A, Ceccagnoli Cohen WM, et al. R&D and the Patent Premium. Int J Indust Organ 2003;26:1153-79
- National Center for Science and Engineering Statistics. Business Research and Development and Innovation: 2008–10, Detailed Statistical Tables NSF 13-332. National Science Foundation, Arlington, VA; 2013. Available from: http://www.nsf.gov/statistics/nsf13332/ [Last accessed 3 November 2014]
- LES Foundation. Surveys of the licensing industry. Available from: http://www.lesfoundation.org/survey [Last accessed 30 September 2014]